Media.Player

NMDAR

總結

Peripherally acting NMDAR antagonists as new anti-diabetic medication. Novel approach for the reduction of blood sugar levels without risk of hypoglycaemia.

技術優勢

Novel approach for reduction of blood sugar levels without risk of Hypoglycaemia
Preclinical evidence of protection of insulin-secreting beta cells
Possible prevention or delay of diabetes Progression
Good results with starting substance in two clinical studies on human type 2 diabetics (Phase IIa)
Possible enhanced safety and reduced adverse effects compared to the OTC drug dextromethorphan

技術應用

Antidiabetic Medication

詳細技術說明

DXO-derivatives that do not efficiently pass the blood brain barrier (BBB), and thus should cause fewer adverse effects on the CNS, but maintain their antidiabetic properties. Therefore, the derivatives might maintain the good safety profile and antidiabetic properties of its starting substance dextrorphan, but with fewer adverse effects.

合作類型

Licensing

申請日期

02/12/2016 00:00:00

申請號碼

EP20160805448 20161202

分類

- international:
A61K31/485; A61P25/00; A61P3/00; A61P35/00; C07D221/28; C07D401/04
- cooperative:
A61P3/10; C07D221/28; C07D401/04

其他

Patent application

ID號碼

4501

國家/地區

德國